Semaglutide to Reduce Atrial Fibrillation Burden
A phase 4 trial registered on ClinicalTrials.gov. The registry status is suspended. It plans to enroll 132 participants.
Also called NCT05209165
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 132 participants
- Sponsor
- San Francisco Veterans Affairs Medical Center
- Registry
-
NCT05209165
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Suspended
Technical summary
Registry record NCT05209165. Randomized; quadruple masking; primary purpose treatment. Start 2023-05 (anticipated); primary completion 2027-05 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Semaglutide to Reduce Atrial Fibrillation Burden
- Condition
- Atrial Fibrillation
- Condition
- Obesity
- Condition
- Overweight
- Intervention (Drug)
- Semaglutide
- Intervention (Drug)
- Placebo
- Lead sponsor
- San Francisco Veterans Affairs Medical Center
Record details
- Record id
cardio:ct-nct05209165- Content hash
5cba25dc2172e9b12404776baaf0be7d1b863530a912e4fc36c0d1a778a2ebdb